Kidney injury and disease in patients with haematological malignancies.

Bridoux, Frank, Cockwell, Paul, Glezerman, Ilya, Gutgarts, Victoria, Hogan, Jonathan J, Jhaveri, Kenar D, Joly, Florent, Nasr, Samih H, Sawinski, Deirdre and Leung, Nelson (2021) Kidney injury and disease in patients with haematological malignancies. Nature reviews. Nephrology. ISSN 1759-507X.

Full text not available from this repository.
Official URL:


Acute kidney injury (AKI) is common in patients with cancer, especially in those with haematological malignancies. Kidney injury might be a direct consequence of the underlying haematological condition. For example, in the case of lymphoma infiltration or extramedullary haematopoiesis, it might be caused by a tumour product; in the case of cast nephropathy it might be due to the presence of monoclonal immunoglobulin; or it might result from tumour complications, such as hypercalcaemia. Kidney injury might also be caused by cancer treatment, as many chemotherapeutic agents are nephrotoxic. High-intensity treatments, such as high-dose chemotherapy followed by haematopoietic stem cell transplantation, not only increase the risk of infection but can also cause AKI through various mechanisms, including viral nephropathies, engraftment syndrome and sinusoidal obstruction syndrome. Some conditions, such as thrombotic microangiopathy, might also result directly from the haematological condition or the treatment. Novel immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor T cell therapy, can also be nephrotoxic. As new therapies for haematological malignancies with increased anti-tumour efficacy and reduced toxicity are developed, the number of patients receiving these treatments will increase. Clinicians must gain a good understanding of the different mechanisms of kidney injury associated with cancer to better care for these patients.

Item Type: Article
Subjects: WJ Urogenital system. Urology
Related URLs:
Depositing User: Mrs Caroline Tranter
Date Deposited: 09 Apr 2021 12:57
Last Modified: 09 Apr 2021 12:57

Actions (login required)

View Item View Item